Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received an average rating of “Moderate Buy” from the fourteen brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $54.6154.

CLDX has been the subject of several recent research reports. Barclays upped their price target on shares of Celldex Therapeutics from $45.00 to $48.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. HC Wainwright reiterated a “buy” rating and set a $42.00 price target on shares of Celldex Therapeutics in a research report on Monday, June 15th. Guggenheim boosted their target price on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Friday, July 17th. Finally, Cantor Fitzgerald cut their price target on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating on the stock in a report on Wednesday, July 22nd.

Institutional Investors Weigh In On Celldex Therapeutics

Institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its position in Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after buying an additional 501 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Celldex Therapeutics by 1.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after buying an additional 680 shares in the last quarter. ProShare Advisors LLC raised its position in Celldex Therapeutics by 6.9% in the fourth quarter. ProShare Advisors LLC now owns 11,973 shares of the biopharmaceutical company’s stock worth $325,000 after purchasing an additional 773 shares in the last quarter. Handelsbanken Fonder AB lifted its position in shares of Celldex Therapeutics by 5.0% during the 2nd quarter. Handelsbanken Fonder AB now owns 27,200 shares of the biopharmaceutical company’s stock worth $1,012,000 after buying an additional 1,300 shares during the period. Finally, Panagora Asset Management Inc. lifted its holdings in shares of Celldex Therapeutics by 7.5% during the fourth quarter. Panagora Asset Management Inc. now owns 21,856 shares of the biopharmaceutical company’s stock valued at $594,000 after acquiring an additional 1,522 shares during the period.

Celldex Therapeutics Price Performance

Shares of CLDX opened at $38.49 on Friday. Celldex Therapeutics has a 12-month low of $19.72 and a 12-month high of $40.30. The business’s fifty day moving average price is $34.15 and its 200 day moving average price is $30.98. The stock has a market capitalization of $3.02 billion, a PE ratio of -9.04 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.18) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.03). The company had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $0.80 million. As a group, research analysts anticipate that Celldex Therapeutics will post -4.36 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.